AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2022
Jan 4, 2022
31523_dirs_2022-01-04_b36959da-e951-4227-84f2-d7cd3597bc81.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2021-12-31
Reporting Person: Campbell Bradley L (Director, Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Common Stock | F | 17597 | $11.55 | Disposed | 439671 | Direct |
| 2022-01-02 | Common Stock | F | 27946 | $11.55 | Disposed | 411725 | Direct |
| 2022-01-03 | Common Stock | F | 4984 | $12.11 | Disposed | 406741 | Direct |
| 2022-01-03 | Common Stock | M | 5470 | $3.53 | Acquired | 412211 | Direct |
| 2022-01-03 | Common Stock | S | 5470 | $11.8611 | Disposed | 406741 | Direct |
| 2022-01-03 | Common Stock | A | 154711 | — | Acquired | 561452 | Direct |
| 2022-01-04 | Common Stock | F | 7368 | $12.48 | Disposed | 554084 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-03 | Stock Options (right to buy) | $3.53 | M | 5470 | Disposed | 2023-01-28 | Common Stock (5470) | Direct |
| 2022-01-03 | Stock Options (right to buy) | $12.11 | A | 283555 | Acquired | 2032-01-03 | Common Stock (283555) | Direct |
Footnotes
F1: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.36 to $12.11. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
F4: The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023.
F5: All of the options were fully vested and exercisable as of the transaction date.
F6: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.